v3.26.1
Segment Reporting
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company has one reportable segment relating to the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. The Company’s Chief Operating Decision Maker (“CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the condensed consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and the change in fair value of warrants are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the condensed consolidated statements of cash flows. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the CODM and are reported on the condensed consolidated statements of cash flows. All long-lived assets are located in the United States. The following table presents certain financial data for the Company’s reportable segment (in thousands):
Three months ended March 31,
20262025
Clinical trial expenses$1,181 $4,192 
Employee related research and development expenses2,684 2,298 
Chemistry, manufacturing and controls expenses1,736 646 
Other research and development expenses1,171 1,136 
Contract and grant reimbursements— (489)
Employee related general and administrative expenses1,810 1,087 
Professional fees and other general and administrative expenses2,020 1,866 
Other segment items(1)
1,221 473 
Segment net loss$11,823 $11,209 
Total segment assets$22,689 $28,178 
(1)Other segment items include interest income, interest expense, and change in the fair value of liability-classified warrants.